| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909291 | Leukemia Research | 2011 | 6 Pages |
Abstract
NT-proBNP provides diagnostic and prognostic information in heart syndromes but its role in cancer has not yet been established. The prognostic value of NT-proBNP was prospectively studied in 104 non-Hodgkin lymphoma (NHL) patients treated with chemotherapy. Echocardiography and NT-proBNP were determined prior to treatment. In multivariate analysis, NT-proBNP â¥Â 900 pg/ml was the variable with higher risk of death (adjusted hazard ratio 11.1; 95% CI 3.8-32.9; P < 0.001). The C statistic for NT-proBNP â¥Â 900 pg/ml was significantly better than IPI score for prediction of survival. These findings suggest that NT-proBNP â¥Â 900 pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eva Gimeno, Miquel Gómez, Juan Ramón González, Josep ComÃn, Alberto Alvarez-Larrán, Blanca Sánchez-González, Lluis Molina, Eva Domingo-Domenech, Francesc Garcia-Pallarols, Carmen Pedro, Eugenia Abella, Carles Vilaplana, Silvia de Sanjosé,